https://www.selleckchem.com/pr....oducts/sacituzumab-g
1% of patients developed recurrent PE, and 46.0% developed constrictive pericarditis. The colchicine treatment group showed a significantly lower risk of composite events (adjusted hazard ratio [aHR] 0.65; 95% confidence interval [CI] 0.49 to 0.87; p=0.003) as well as all-cause death (aHR 0.60; 95%CI 0.45 to 0.81; p=0.001) than did the noncolchicine group. On propensity score matching, colchicine after PCC was consistently associated with a lower composite events (aHR 0.55; 95%CI 0.37 to 0.82; p=0.003). In cancer patients
Like
Comment
Share
